Quillaja saponin adjuvant and vaccine formulation containing same
US5817314A · kind A · utility
10Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 1996 |
| Grant date | Oct 6, 1998 |
| Priority date | — |
| Expiry date | Dec 6, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55577
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel saponin component having a molecular weight of about 956 daltons, a process for isolating the saponin component from the bark of Quillaja saponaria Molina, a vaccine formulation comprising the saponin component as an immune adjuvant, a method for increasing the immune response to an antigen by employing an adjuvant composition comprising saponin component and a second adjuvant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.